Choroidal Thickening Induced by Pioglitazone in Diabetic Patients

• Published in: Korean journal of ophthalmology 2024, 38(5), , pp.331-341
• Main Authors: Lee, Ju Seouk, Kim, Chang Zoo, Lee, Seung Uk, Lee, Sang Joon
• Format: Article
• Language: English
• Subjects: Administration, Oral; Aged; Choroid - diagnostic imaging; Choroid - drug effects; Choroid - pathology; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Female; Follow-Up Studies; Glycated Hemoglobin - metabolism; Humans; Hypoglycemic Agents - administration & dosage; Male; Middle Aged; Original; Pioglitazone - administration & dosage; Pioglitazone - therapeutic use; Retrospective Studies; Thiazolidinediones - administration & dosage; Thiazolidinediones - therapeutic use; Tomography, Optical Coherence - methods; Visual Acuity; 안과학
• ISSN: 1011-8942; 2092-9382; 2092-9382
• DOI: 10.3341/kjo.2024.0039

This study aimed to determine the changes in choroidal thickness induced by pioglitazone in diabetic patients. A total of 261 patients diagnosed with type 2 diabetes who had taken oral pioglitazone for more than 6 months were included in the study. After excluding patients who did not undergo regular eye examinations or who had ophthalmic surgery/interventions during the treatment period, a total of 40 eyes were included. The study examined the duration and dosage of pioglitazone, patient age, ocular axial length, refraction, glycated hemoglobin, systolic blood pressure, corrected visual acuity, macular thickness, choroidal thickness, and choroidal vascular index. Patients were categorized into a high-dose group if their pioglitazone dose was 30 mg or more per day, and a low-dose group if it was 15 mg or less. Choroidal thickness was measured below the subfovea and a 500 µm radius nasal and temporal to that location. Choroidal thickness significantly increased after 6 and 12 months of pioglitazone (6.70 and 13.65 µm, respectively) in all subjects. When stratified by pioglitazone dosage, choroidal thickness increased at 6 and 12 months in both high-dose group (4.48 and 0.84 µm, respectively) and low-dose groups (6.85 and 21.45 µm, respectively), with a greater change observed in the low-dose group (p < 0.05). Based on the location of choroidal thickness measurements, a significant increase in choroidal thickness was observed at 6 and 12 months of pioglitazone treatment in the subfoveal (7.00 and 13.15 µm, respectively) and nasal regions (6.43 and 19.24 µm, respectively), while a significant increase was only observed after 6 months of treatment in the temporal region (8.53 µm, p < 0.05). The largest increase in choroidal thickness was observed in the nasal side. This study found that choroidal thickness increased in diabetic patients after taking pioglitazone. Regular eye examinations are recommended for diabetic patients who are on pioglitazone.